News Release

New appointment brings global financial and operational experience in life sciences to support continued advancement of ReAlta’s EPICC Technology Platform

Norfolk, VA – July 9, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of Emma Reeve to its Board of Directors, effective immediately.

“We are very pleased to welcome Emma Reeve to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors. “As ReAlta continues to advance our programs towards commercial launch in markets around the world, Emma’s diverse global experience and deep knowledge of capital markets and financial strategies will help guide and strengthen our plans to deliver novel therapies to the patients that urgently need them.”

“I am impressed with the remarkable progress ReAlta has made to advance multiple programs into the clinic,” said Ms. Reeve. “I am excited to take on this role and contribute to the company’s mission to address life threatening acute inflammatory and rare diseases.”

Emma Reeve

Emma Reeve is an accomplished biopharmaceutical executive with more than 30 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, Ms. Reeve served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. She led Constellation’s IPO in 2018.

Prior to Constellation, Ms. Reeve acted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out. Earlier in her career, Ms. Reeve served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol Myers Squibb, Merck, and Novartis.

Ms. Reeve is currently Chair of the Board of Editas Medicine and serves on the Board of PTC Therapeutics and Aadi Bioscience, all public biotechnology companies. In addition, she serves on the Board of Directors for Cardurion Pharma. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England and Wales.

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance by the U.S. Food and Drug Administration (FDA) for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease, and IND clearance, Orphan Drug Designation, and Fast Track Designation by the FDA, and Orphan Drug Designation by the European Medicines Agency, for the treatment of hypoxic-ischemic encephalopathy (HIE). The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

Media and Investor Contact:
John Rickman
Chief Financial Officer
jrickman@realtals.com